In a significant boost to the biotech industry, SanegeneBio, a global clinical-stage biotech company backed by leading investors including Tencent, has successfully raised over $110 million in its Series B financing round.
This landmark funding, announced on December 9, 2025, underscores growing investor confidence in SanegeneBio’s innovative approach to RNA-based therapeutics.
SanegeneBio’s Mission to Transform Healthcare
With its corporate headquarters in Boston, USA, and major R&D operations in Suzhou, China, SanegeneBio is focused on developing cutting-edge RNAi (RNA interference) medicines aimed at treating cardiometabolic diseases.
The company’s proprietary RNAi delivery platform is designed to overcome long-standing challenges in achieving precise tissue targeting—an essential barrier in optimizing the effectiveness of RNA-based therapeutics.
A Strategic Partnership with Eli Lilly
Adding to its momentum, SanegeneBio recently entered a $1.2 billion research collaboration with pharmaceutical giant Eli Lilly to advance next-generation cardiometabolic RNA therapies, according to reporting from Fierce Biotech.
This high-profile partnership highlights the global potential of SanegeneBio’s scientific platform and its ability to attract world-class industry partners.
Historical Growth and Investor Support
SanegeneBio has demonstrated sustained growth since its earlier funding rounds, including an extended Series A co-led by Tencent in 2023, noted by DealStreetAsia.
The latest Series B raise is expected to accelerate clinical trial programs, deepen research capabilities, and expand SanegeneBio’s international footprint—positioning the company as a rising leader in RNA therapeutics.
Future Prospects and Industry Impact
Looking ahead, SanegeneBio aims to fast-track the development of its therapeutic pipeline, with the potential to deliver life-changing treatments for patients in the coming years.
The success of this Series B round is likely to spark renewed investor interest in RNA therapeutics, a field increasingly recognized for its ability to reshape modern medicine.
As SanegeneBio continues to expand globally and push the boundaries of RNA innovation, the biotech community is watching closely to see how its progress will influence the next generation of healthcare breakthroughs.
Alfred Lee
